Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
ABSTARCT Alzheimer's disease (AD) is characterized neuropathologically by an abundance of 1) neuritic plaques, which are primarily composed of a fibrillar 42-amino-acid amyloid- β peptide (A β ), as well as 2) neurofibrillary tangles composed of aggregates of hyperphosporylated tau. Elevations in the concentrations of the A β 42 peptide in the brain, as a result of either increased production or decreased clearance, are postulated to initiate and drive the AD pathologic process. We initially introduced a novel class of bridged aromatics referred t γ -secretase modulatoro as γ -secretase modulators that inhibited the production of the A β 42 peptide and to a lesser degree the A β 40 peptide while concomitantly increasing the production of the carboxyl-truncated A β 38 and A β 37 peptides. These modulators potently lower A β 42 levels without inhibiting the γ -secretase–mediated proteolysis of Notch or causing accumulation of carboxyl-terminal fragments of APP. In this study, we report a large number of pharmacological studies and early assessment of toxicology characterizing a highly potent γ -secretase modulator (GSM), ( S )- N -(1-(4-fluorophenyl)ethyl)-6-(6-methoxy-5-(4-methyl-1 H -imidazol-1-yl)pyridin-2-yl)-4-methylpyridazin-3-amine (BPN-15606). BPN-15606 displayed the ability to significantly lower A β 42 levels in the central nervous system of rats and mice at doses as low as 5–10 mg/kg, significantly reduce A β neuritic plaque load in an AD transgenic mouse model, and significantly reduce levels of insoluble A β 42 and pThr181 tau in a three-dimensional human neural cell culture model. Results from repeat-dose toxicity studies in rats and dose escalation/repeat-dose toxicity studies in nonhuman primates have designated this GSM for 28-day Investigational New Drug-enabling good laboratory practice studies and positioned it as a candidate for human clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“…and statistically significant reduction in cognitive decline as measured by MiniMentalStateExaminationandClinicalDementiaRating, relative to placebo, lending significant support to therapeutic strategies targeting plaque-associated Ab peptides for the treatment of AD (Sevigny et al., 2016).”
BackgroundTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“In contrast, immunotherapy approaches that aim at clearing deposited Ab peptides have recently shown potential against AD; however, this is only after years of failures (Gilman et al., 2005; Miles et al., 2013; Salloway et al., 2014).”
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Self-citationIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · cited 1×
“The neuritic plaques associated with AD are composed predominantly of Ab42 (Iwatsubo et al., 1994), and the most common biochemical phenotype observed for the more than 200 different familial AD–linked mutations is an increased ratio of Ab42/Ab40 (Kumar-Singh et al., 2006; Potter et al., 2013).”
BackgroundJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 9×
“It is well established that the specific transgenicmousemodel used in this study (PSAPP) develops Ab deposits by 2–3 months of age with reliable onset of Ab neuritic plaques at 6 months of age (Jankowsky et al., 2004; Zhang et al., 2016).”
InfluentialSelf-citationClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261 · cited 2×
“A number of potential disease-modifying therapeutic approaches for AD either have previously failed or are currently just beginning to be tested clinically, yet none to date have been shown to impact disease progression (Qiu et al., 2009; Sabbagh and Cummings, 2011).”
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
A three-dimensional human neural cell culture model of Alzheimer’s disease
Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195 · cited 4×
“, BACE inhibitors) have also been shown to impact p-tau pathology in this 3D human culture system (Choi et al., 2014).”
InfluentialSelf-citationCirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08844.2003 · Cited by 394 · cited 1×
“…lowering plasma Ab levels than either brain or CSF Ab levels probably due to the higher exposures of free drug in plasma (see Supplemental Tables 6 and 7) as well as the shorter half-life of plasma Ab peptides compared with the central nervous system turnover of Ab peptides (Cirrito et al., 2003).”
BackgroundIncreased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236 · cited 1×
“The neuritic plaques associated with AD are composed predominantly of Ab42 (Iwatsubo et al., 1994), and the most common biochemical phenotype observed for the more than 200 different familial AD–linked mutations is an increased ratio of Ab42/Ab40 (Kumar-Singh et al., 2006; Potter et al., 2013).”
Miles, L. A., Crespi, G. A. N., Doughty, L., & Parker, M. W. (2013) · Scientific Reports · doi:10.1038/srep01302 · Cited by 130 · cited 1×
“In contrast, immunotherapy approaches that aim at clearing deposited Ab peptides have recently shown potential against AD; however, this is only after years of failures (Gilman et al., 2005; Miles et al., 2013; Salloway et al., 2014).”
Cited by
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
The innate immunity protein IFITM3 modulates γ-secretase in Alzheimer’s disease
Hur, J.-Y., Frost, G. R., Wu, X., Crump, C., Pan, S. J., Wong, E., Barros, M., Li, T., Nie, P., Zhai, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2681-2 · Cited by 382
Self-citationTargeting Notch in oncology: the path forward
Majumder, S., Crabtree, J. S., Golde, T. E., Minter, L. M., Osborne, B. A., & Miele, L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00091-3 · Cited by 270
Kwak, S. S., Washicosky, K. J., Brand, E., von Maydell, D., Aronson, J., Kim, S., Capen, D. E., Cetinbas, M., Sadreyev, R., Ning, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15120-3 · Cited by 151
Self-citationPreclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202560 · Cited by 76
Self-citation
Metadata
- Authors
- Wagner, S. L., Rynearson, K. D., Duddy, S. K., Zhang, C., Nguyen, P. D., Becker, A., Vo, U., Masliah, D., Monte, L., Klee, J. B., Echmalian, C. M., Xia, W., Quinti, L., Johnson, G., Lin, J. H., Kim, D. Y., Mobley, W. C., Rissman, R. A., & Tanzi, R. E.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 362
- Issue
- 1
- Pages
- 31-44
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2606115324
- Cited by
- 49
- References
- 12
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.